- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Oral difelikefalin effective in reducing atopic dermatitis- associated pruritus: Study
USA: In a recent study, the researchers observed a rapid, significant anti-pruritic effect of difelikefalin (DFK) in an atopic dermatitis (AD) mouse model and in subjects having mild-to-moderate AD. The results of the study support DFK's role as an anti-pruritic agent for itch-predominant AD patients.
The findings were presented at the AAAAI annual meeting 2022 and subsequently published in the Journal of Allergy and Clinical Immunology.
Many AD patients exhibit itch that is disproportionate to rash. In AD, only limited therapies specifically target itch. Difelikefalin is a selective kappa-opioid receptor agonist that is being developed for chronic pruritic conditions.
In the phase 2, randomized, double-blind study, Brian Kim, Washington University School of Medicine, and colleagues enrolled adults with AD and moderate-to-severe pruritus. They received oral placebo (PBO) or DFK (0.25, 0.5, or 1.0 mg) BID for 12 weeks. Also, mice with topical MC903-induced AD were treated with DFK (0.5 mg/kg) intraperitoneally and itch was assessed early (30 minutes).
Change from baseline in mean Itch Numerical Rating Scale (I-NRS) and >_4-point improvement in I-NRS at week 12 were the primary and key secondary endpoints.
The research led to the following findings:
- In mice, DFK promoted rapid, significant itch reduction independently of skin inflammation.
- Among 401 subjects randomized, ;64% had mild-to-moderate AD.
- In the overall population, treatment difference in mean I-NRS change between the combined DFK group (all doses) and PBO was 20.43 at week 12.
- In subjects with mild- to-moderate AD, a significant difference in mean I-NRS was observed at week 12 (20.75) in the DFK group versus PBO (P50.036); a significantly greater proportion of subjects achieved >_4-point improvement in I-NRS with DFK. Itch reduction was observed early (week 1).
- Adverse events with DFK were most commonly abdominal pain, nausea, dry mouth, head- ache, dizziness, and hypertension.
"We observed a rapid, significant anti-pruritic effect of DFK in an AD mouse model and in patietns with mild-to-moderate AD," wrote the authors. "The findings supports DFK's role as an anti-pruritic agent for patients with itch-predominant AD."
Reference:
The study titled, "Oral Difelikefalin Reduces Atopic Dermatitis–Associated Pruritus," was published in the Journal of Allergy and Clinical Immunology.
DOI: https://doi.org/10.1016/j.jaci.2021.12.075
KEYWORDS: atopic dermatitis, difelikefalin, pruritis, Journal of Allergy and Clinical Immunology, anti-pruritic, AAAAI annual meeting 2022, skin inflammation, skin disease, itching, rash
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751